Management of rheumatoid arthritis

National Medical Journal of India

Volumn 17, Issue 3, 2004, Pages 143-151

  Handa, Rohini ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; BUCILLAMINE; CELECOXIB; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXYCYCLINE; ETANERCEPT; ETORICOXIB; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; LEVAMISOLE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; VALDECOXIB;

AGRANULOCYTOSIS; ALOPECIA; ANGINA PECTORIS; APLASTIC ANEMIA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLADDER CANCER; BONE MARROW SUPPRESSION; CATARACT; CELLULITIS; CHILL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DEMYELINATING DISEASE; DIARRHEA; DISEASE EXACERBATION; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED CANCER; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GONAD DYSFUNCTION; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INFECTION; INFUSION REACTION; INJECTION PAIN; INJECTION SITE REACTION; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER INJURY; LIVER TOXICITY; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS; LYMPHOMA; MONOTHERAPY; MOUTH ULCER; MUCOSA INFLAMMATION; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OLIGOSPERMIA; PANCYTOPENIA; PNEUMONIA; PROTEINURIA; PSYCHOSIS; RETINA DISEASE; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINUSITIS; SKIN PIGMENTATION; STEVENS JOHNSON SYNDROME; STOMATITIS; TERATOGENICITY; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VISUAL IMPAIRMENT; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042850465     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Vliet Vlieland TP. Rehabilitation of people with rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:847-61.
2. Van Den Ende CH, Vliet Vlieland TP, Munneke M, Hazes JM. Dynamic exercise therapy for rheumatoid arthritis. Cochrane Database Syst Rev 2000;2:CD000322.
3. Whittle BJ. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 2003;17:301-13.
4. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: Evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253: 643-52.
5. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow up of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
6. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
7. Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M'Seffar A, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: A 3-year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000;27:623-9.
8. O'Dell JR. Treating rheumatoid arthritis early: A window of opportunity? Arthritis Rheum 2002;46:283-5.
9. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. FIN-RACo Trial Group. Finnish Rheumatoid Arthritis Combination therapy. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
10. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 (Suppl 2):74-8.
11. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995;22:1792-6.
12. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. J Rheumatol 1998;25:1072-7.
13. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration. Arthritis Rheum 2000;43:22-9.
14. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. van der Heijde DMFM, van't Hof MA, van Riel PLCM, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
17. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
18. van Riel PLCM, Schumacher HR Jr. How does one assess early rheumatoid arthritis in daily clinical practice? Best Pract Res Clin Rheumatol 2001;15:67-76.
19. Fransen J, Stucki G, van Riel PLCM. Rheumatoid Arthritis Measures. Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum (Arthritis Care & Res) 2003;49: S214-S224.
20. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of the global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
21. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
22. Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am 1997;23:149-67.
23. Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol 1992;28:148-52.
24. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000;160:610-19.
25. McCarty DJ. Personal experience in the treatment of seropositive rheumatoid arthritis with drugs used in combination. Semin Arthritis Rheum 1993;23 (2 Suppl 1):42-9.
26. Boers M, Ramsden M. Long acting drug combinations in rheumatoid arthritis: A formal overview. J Rheumatol 1991;18:316-24.
27. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis: A meta-analysis. Arthritis Rheum 1994;37:1487-91.
28. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: Updated systematic review. Br J Rheumatol 1998;37:612-19.
29. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
30. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
31. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
32. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: A five-year randomized follow up trial. Arthritis Rheum 2004;50:55-62.
33. Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 2001;19:715-28.
34. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoide Artritis. Br J Rheumatol 1998;37:1102-9.
35. O'Dell JR. Combinations of conventional disease modifying antirheumatic drugs. Rheum Dis Clin North Am 2001;27:415-26.
36. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:723-31.
37. Committee for RA Guidelines, Indian College of Physicians. Indian Guidelines for the management of Rheumatoid Arthritis. J Assoc Physicians India 2002;50:1201-18.
38. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF, for the American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. A report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-82.
39. Kremer JM, Alarcon GS, Weinblatt ME, Koymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate associated lung injury in patients with rheumatoid arthritis. A multicenter study with literature review. Arthritis Rheum 1997;40:1829-37.
40. Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
41. Pincus T. Guidelines for monitoring of methotrexate therapy: 'Evidence-Based Medicine' outside of clinical trials. Arthritis Rheum 2003;48:2706-9.
42. Cartwright VW, Michaud K, Choi HK: et al. Methotrexate, laboratory testing, and risk, of serious illness: Analyses in 20 000 patients. Arthritis Rheum 2003;48 (Suppl): S428-S429.
43. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142-6.
44. Kirwan JR. Systemic low-dose glucocorticoid treatment in rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:389-403.
45. Criswell LA, Saag KG, Sems KM, Welch V, Shea B, Wells G, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev 2000;2:CD001158.
46. Handa R. Interventional rheumatology: An emerging new concept. J Assoc Physicians India 2004;52:275-7.
47. Handa R. Immunointerventions in rheumatoid arthritis. J Indian Rheum Assoc 1996;4:134-45.
48. O'Dell JR. Anticytokine therapy - A new era in the treatment of rheumatoid arthritis? N Engl J Med 1999;340:310-12.
49. Jones RE, Morelard LW. Tumour necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 1999;48:1-4.
50. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kaiden JR, et al. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
51. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
52. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
53. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
54. Nuki G, Bresnihan B, Bear MB, McCabe D, for the European Group of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. A rthritis Rheum 2002;46:2838-46.
55. Klareskog L. Data presented at EULAR 2003 satellite symposium. Lisbon, Portugal; June 12-15, 2003. Available at: http.//www.hopkins-arthritis.org/ed/eular2003/ra-treatments-tnf.html (accessed 7 May 2004).
56. Emery P, Reginster JY, Appelboom T, Breedveld FC, Edelmann E, Kekow J, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 2001;40:699-702.
57. Hoffman K. Medical management of rheumatoid arthritis. Clinician Rev 2003;13:48-53.
58. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.
59. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbre1) has failed or vice versa: Data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
60. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
61. Smolen JS, Emery P, Bathon J, et al. Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone: Preliminary results of the ASPIRE trial [Abstr]. Ann Rheum Dis 2003;62 (Suppl 1):64.
62. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Antitumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect 2003;3:148-55.
63. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
64. De Rosa FG, Bonora S, Di Perri G. Tuberculosis and treatment with infliximab. N Engl J Med 2002;346:623-6.
65. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
66. Reimold AM. TNF alpha as therapeutic target: New drugs, more applications. Curr Drug Targets Inflamm Allergy 2002;1:377-92.